Welcome to our dedicated page for Sutro Biopharma SEC filings (Ticker: STRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sutro Biopharma, Inc. (STRO) SEC filings page on Stock Titan provides access to the company’s public filings as reported to the U.S. Securities and Exchange Commission. Sutro is a clinical-stage oncology company focused on antibody-drug conjugates (ADCs), and its filings offer detailed insight into how it reports financial results, manages risk, and discloses material events related to its ADC pipeline and corporate operations.
Investors can review current reports on Form 8-K, where Sutro has disclosed items such as quarterly financial results, organizational restructuring designed to prioritize its ADC programs and extend its cash runway, and notices from Nasdaq regarding minimum bid price compliance. Additional 8-K filings describe actions like the 1-for-10 reverse stock split of its common stock and subsequent confirmation that the company regained compliance with Nasdaq Listing Rule 5450(a)(1).
Beyond event-driven 8-Ks, users can use this page to locate annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more extensive information on Sutro’s research and development activities, collaboration agreements, and financial condition. For those tracking management and ownership changes, insider transaction reports on Form 4 and related filings can also be accessed to see how executives and directors transact in STRO shares.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as pipeline updates, restructuring charges, collaboration revenue, and listing status developments. Real-time updates from EDGAR ensure that new Sutro Biopharma filings appear promptly, while AI-generated overviews provide a starting point for deeper review of the full SEC documents.
SUTRO BIOPHARMA, INC. Chief Administrative Officer and General Counsel David Pauling reported multiple equity transactions. He acquired common stock through the vesting and settlement of restricted stock units (RSUs) and received new awards of 4,200 RSUs and stock options for 33,600 shares. Some common shares (970 and 551) were withheld at prices of $20.55 and $20.47 to satisfy tax obligations in connection with RSU settlements, which the company notes do not represent market sales by Pauling.
Sutro Biopharma Chief Scientific Officer Hans-Peter Gerber reported multiple equity transactions involving restricted stock units (RSUs), stock options and common shares. On March 1 and 2, 2026, RSU vesting led to the acquisition of 1,125 and 2,843 shares of common stock through derivative exercises at a stated price of
To cover income tax withholding obligations related to these RSU settlements, the issuer withheld 463 and 1,170 shares of common stock at prices of
SUTRO BIOPHARMA, INC. reported that its CFO, Gregory K. Chow, received new equity awards. He was granted stock options covering 40,000 shares of common stock at an exercise price of $0.00 per share, and 5,000 Restricted Stock Units (RSUs), both held directly.
According to the vesting terms, 1/48 of the stock option award vests monthly, starting on April 1, 2026, contingent on his continued service. The 5,000 RSUs vest in four equal annual installments, with the first tranche vesting on March 1, 2027, also subject to continued service, and each RSU represents one share upon settlement.
Sutro Biopharma CEO Jane Chung reported multiple equity award and vesting transactions. She received a grant of 40,000 Restricted Stock Units (RSUs) and a stock option for 175,000 shares, both with service-based vesting schedules over time.
RSUs previously granted to her vested on March 1 and March 2, 2026, and were settled into common stock through several derivative exercises. In connection with these vestings, a total of 2,779 shares at $20.55 and 1,271 shares at $20.47 of common stock were withheld by the company to cover income tax obligations, which the footnotes state do not represent sales by the reporting person.
Sutro Biopharma reports institutional holdings by BVF group. As of
The filing states aggregate positions that certain BVF-related entities may be deemed to beneficially own: 1,157,609 shares held by BVF GPH and 1,251,788 shares attributed to Partners, BVF Inc. and Mark N. Lampert, representing approximately
Sutro Biopharma, Inc. filed an amended Schedule 13G/A showing that Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen no longer beneficially own any of its common stock. As of the event date of 12/31/2025, each reporting person discloses beneficial ownership of 0 shares, representing 0% of Sutro’s common stock, with no sole or shared voting or dispositive power.
The filing confirms that the group now owns 5% or less of the class. It also notes that all securities previously reported were directly owned by advisory clients of Suvretta Capital Management, LLC, and that no individual advisory client is deemed to own more than 5% of the common stock. The certification states that the securities were not acquired and are not held for the purpose of changing or influencing control of Sutro Biopharma.
Sutro Biopharma, Inc. investors received an update on institutional ownership as Suvretta Capital Management, Averill Master Fund, and Aaron Cowen reported no beneficial ownership of the company’s common stock. Each reporting person lists 0 shares beneficially owned, representing 0% of the class, with no sole or shared voting or dispositive power.
The filing notes that all securities previously reported are directly owned by advisory clients of Suvretta Capital Management, and that none of those clients may be deemed to beneficially own more than 5% of Sutro’s common stock. The reporting persons also certify that the securities are not held to change or influence control of the company.
Sutro Biopharma, Inc. entered an underwriting agreement on February 9, 2026 to sell 7,868,383 shares of common stock at $13.98 per share in an underwritten public offering under its existing shelf registration. The company estimates gross proceeds of about $110.0 million, which, combined with its cash, cash equivalents and marketable securities as of January 1, 2026, is expected to bring total capital resources to approximately $251.4 million.
Sutro plans to use the net proceeds primarily for general corporate purposes, including research, clinical and process development and manufacturing of product candidates, working capital, potential acquisitions or investments, capital expenditures and other corporate needs. Based on its planned use of funds, Sutro estimates this capital will fund operating and capital needs into the second quarter of 2028. The offering is expected to close on February 11, 2026, subject to customary conditions. Sutro is also releasing an updated corporate presentation, which will be available on its website and furnished as an exhibit.
Sutro Biopharma, Inc. is conducting a primary offering of 7,868,383 shares of common stock at $13.98 per share, raising gross proceeds of $109,999,994. After $6,600,000 in underwriting discounts and commissions, Sutro expects approximately $103,399,995 in proceeds before expenses and estimates net proceeds of about $102.7 million.
The company plans to use the cash, together with existing balances, for general corporate purposes, including research, clinical and process development, manufacturing, working capital, potential acquisitions or investments, and capital expenditures. Combined with cash, cash equivalents and marketable securities as of January 1, 2026 and the additional $110.0 million before costs, Sutro expects to have approximately $251.4 million in capital resources, which it estimates will fund operations into the second quarter of 2028.
As context, 8,563,888 shares of common stock were outstanding as of September 30, 2025. The offering price of $13.98 per share is expected to result in immediate dilution of $13.04 per share to new investors, based on an as adjusted net tangible book value of $0.94 per share after the transaction. Leerink Partners LLC, TD Securities (USA) LLC and LifeSci Capital LLC are underwriting the deal, and the company, its directors and executive officers are subject to 60‑day and 90‑day lock-up periods, respectively, with specified exceptions.
Affinity Asset Advisors, LLCMichael Cho report beneficial ownership of 748,382 shares of Sutro Biopharma, Inc. common stock, equal to approximately 8.8% of the company’s outstanding shares based on 8,519,392 shares outstanding as of December 3, 2025.
The shares are held by Affinity Healthcare Fund, LP, for which Affinity Asset Advisors serves as investment manager. As of the current reporting date, the reporting persons have sole voting and dispositive power over these shares and certify that the position is held in the ordinary course of business, without the purpose or effect of changing or influencing control of Sutro Biopharma.